Clinical Features of Extragastrointestinal Stromal Tumor Compared with Gastrointestinal Stromal Tumor: A Retrospective, Multicenter, Real-World Study

Table 2

Cox regression model to evaluate the association of EGIST with OS or DFS before propensity score matching.

Factors	HR (95% CI)
	OS		DFS
	Univariate analysis	Multivariate analysis	Univariate analysis	Multivariate analysis
Sex female (vs. male)	1.14 (0.62–2.11)		0.74 (0.36–1.52)
Age >60 years (vs. ≤60 years)	1.93 (1.01–3.69)	1.72 (0.85–3.48)	0.98 (0.49–1.97)
ECOG 1 (vs. ECOG 0)	1.04 (0.50–2.17)		1.02 (0.44–2.34)
ECOG >1 (vs. ECOG 0)	0.89 (0.32–2.45)		1.17 (0.41–3.39)
Tumor size >10 cm (vs. ≤10 cm)	2.28 (1.23–4.23)	1.18 (0.55–2.54)	2.69 (1.35–5.40)	1.36(0.63–2.94)
Tumor necrosis yes (vs. no)	1.54 (0.83–2.88)	0.74 (0.36–1.52)	2.96 (1.47–5.95)
Tumor mitosis >5/50 HPF (vs. ≤5/50 HPF)	3.03 (1.59–5.79)	3.50 (1.68–7.28)	1.33 (0.66–2.66)
Histopathological classification spindle (vs. others)	0.50 (0.26–0.97)	0.62 (0.32–1.22)	0.58 (0.27–1.26)	0.60 (0.28–1.31)
Adjuvant therapy accepted (vs. not accepted)	0.54 (0.26–1.09)	0.42 (0.20–0.89)	1.33 (0.66–2.67)	1.66 (0.77–3.59)
Location EGIST (vs. GIST)	2.30 (1.23–4.33)	2.43 (1.13–5.22)	6.31(3.11–12.8)	4.79 (2.20–10.43)

OS: overall survival; DFS: disease-free survival; HR: hazard ratio; CI: confidence interval, ECOG: Eastern Cooperative Oncology Group;.